文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

成人重症患者血糖变异性与院内死亡率的独立关联:来自澳新重症监护学会结局与资源评价双国家注册登记的研究结果

Independent Association of Glucose Variability With Hospital Mortality in Adult Intensive Care Patients: Results From the Australia and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Binational Registry.
PubMed 文献 · Crit Care Explor · 2019-08-01
一句话结论在非高血糖成人ICU患者中,入ICU首个24小时血糖宽度最高四分位与最低四分位相比院内死亡 odds 升高(OR 1.43,95%CI 1.32-1.55),校正基线风险、中点血糖、低血糖事件及ICU间变异后仍独立相关。

该研究为回顾性注册登记数据分析,纳入澳大利亚和新西兰176个ICU、10年间非高血糖成人患者290,966例,以入ICU首个24小时最高与最低血糖浓度之差(血糖宽度)衡量血糖变异性。采用分层混合效应logistic回归校正ICU间变异及多个固定效应协变量后,血糖宽度与院内死亡率独立相关:血糖宽度最高四分位 vs 最低四分位的 OR 为1.43(95%CI 1.32-1.55,P<0.001)。混合效应模型显示该关联在不同ICU间存在统计学显著变异。作者结论认为血糖变异性与危重成人院内死亡率独立相关,并建议未来研究在血糖控制方案中纳入对血糖变异性的校正。

要点

  • 非高血糖成人ICU患者入ICU首个24小时血糖宽度最高四分位 vs 最低四分位,院内死亡 OR 1.43(95%CI 1.32-1.55,P<0.001)。
  • 该关联在校正基线死亡风险、中点血糖水平、低血糖发生及ICU间变异后仍显著。
  • 混合效应模型显示血糖变异性与院内死亡的关联在不同ICU间存在统计学显著变异。
  • 研究基于澳新176个ICU、10年、290,966例非高血糖患者的注册登记数据,为回顾性分析。
  • 作者认为未来研究需探讨在血糖控制方案中纳入对血糖变异性的校正。

适用人群与场景

  • 澳大利亚和新西兰176个ICU注册登记的非高血糖成人重症患者,共290,966例,使用10年数据。

诊断标准与关键阈值

  • 血糖变异性以血糖宽度衡量,定义为入ICU首个24小时内最高与最低血糖浓度之差。
  • 按血糖宽度四分位分组,比较最高四分位 vs 最低四分位的院内死亡风险。

研究设计与关键结果

  • 研究类型为回顾性注册登记数据分析,数据来自澳大利亚和新西兰重症监护学会结局与资源评价成人患者数据库,覆盖176个ICU,纳入非高血糖患者290,966例,无干预。
  • 采用分层混合效应logistic回归模型,校正ICU间变异及多个固定效应协变量。
  • 血糖宽度与院内死亡率独立相关:血糖宽度最高四分位 vs 最低四分位的 OR 为1.43(95%CI 1.32-1.55,P<0.001),该结果在校正基线死亡风险、中点血糖水平、低血糖发生及ICU间变异后仍显著。
  • 混合效应模型显示血糖变异性与院内死亡的关联在不同ICU间存在统计学显著变异。

证据类型、等级与局限

  • 证据类型:回顾性注册登记数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为血糖变异性与危重成人院内死亡率独立相关,提示血糖宽度可能作为院内死亡风险的相关因素。
  • 作者认为未来研究需探讨在血糖控制方案中纳入对血糖变异性的校正。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Wide variations in blood glucose excursions in critically ill patients may influence adverse outcomes such as hospital mortality. However, whether blood glucose variability is independently associated with mortality or merely captures the excess risk attributable to hyperglycemic and hypoglycemic episodes is not established. We investigated whether blood glucose variability independently predicted hospital mortality in nonhyperglycemic critical care patients.

DESIGN: Retrospective, registry data analyses of outcomes.

SETTING: Large, binational registry (Australia and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database repository) of 176 ICUs across Australia and New Zealand.

PATIENTS: We used 10-year data on nonhyperglycemic patients registered in the Australia and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database repository (n = 290,966).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Glucose variability was captured using glucose width defined as the difference between highest and lowest blood glucose concentration within first 24 hours of ICU admission. We used hierarchical, mixed effects logistic regression models that accounted for ICU variation and several fixed-effects covariates. Glucose width was specifically and independently associated with hospital mortality. The association of blood glucose variability with mortality remained significant (odds ratio for highest vs lowest quartile of glucose, 1.43; 95% CI, 1.32-1.55; p < 0.001) even after adjusting for the baseline risk of mortality, midpoint blood glucose level, occurrence of hypoglycemia and inter-ICU variation. Mixed effects modeling showed that there was a statistically significant variation in this association across ICUs.

CONCLUSIONS: Our study demonstrates that glucose variability is independently associated with hospital mortality in critically ill adult patients. Inclusion of correction for glucose variability in glycemic control protocols needs to be investigated in future studies.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Kulkarni H, Bihari S, Prakash S, et al. Independent Association of Glucose Variability With Hospital Mortality in Adult Intensive Care Patients: Results From the Australia and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Binational Registry. Crit Care Explor. 2019. PMID: 32166267. doi:10.1097/CCE.0000000000000025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。